Category: Abbott Laboratories
Media reports in India claim that some of medtech's biggest companies are looking the other way when their Indian distributors hike prices and bribe doctors to use their drug-eluting stents.
Some of medtech's biggest players are getting a beating in the Indian media, where reports this week accused them of turning a blind eye to unethical behavior from their distributors in the country.
A roundup of studies released at the annual Transcatheter Cardiovascular Therapies conference in Washington this week.
Here's a look at some of the news coming out of Washington at the 26th annual Transcatheter Cardiovascular Therapies conference this week:
The Dow Jones Sustainability World Index names Abbott Labs and Medtronic among the healthcare companies with the most sustainable practices.
MASSDEVICE ON CALL — A couple of medtech's biggest players were named among the Dow Jones Sustainability World Index's most environmentally responsible companies.
Abbott (NYSE:ABT) led the sector for the greenest practices, ranked according to "financially material economic, environmental, and social factors."
Abbott Labs pours $60 million into a new manufacturing plant in Malaysia's Kulim Hi-Tech Park.
Chicago healthcare giant Abbott (NYSE:ABT) is preparing to open a new manufacturing facility and add 500 new employees in Malaysia, according to local reports.
FreeStyle Libre system eliminates routine finger pricks for glucose measurements and requires no finger pricks for calibration; available for people living with diabetes in several European markets beginning in the coming weeks; advanced ambulatory glucose profile software presents data in a user-friendly, visual chart, enabling productive treatment discussions.
Abbott lands European CE Mark for its FreeStyle Libre blood glucose meter, a wearable sensor that eliminates the need for routine finger-prick testing.
Illinois-based healthcare giant Abbott (NYSE:ABT) is preparing to launch sales of its novel FreeStyle Libre blood glucose sensing system after getting the stamp of approval from European regulators.
Here's a look at some of the top regulatory stories for medical device companies this week: Masimo reveals FDA warning letter over Pronto 7 monitor; FDA issues new draft guidance on Class III de novos, UDI for small entities; Medicare finalizes coverage for MitraClip